Vnitřní lékařství, 1996 (vol. 42), issue 12

[Urinary oxalic acid excretion in chronic kidney failure and after kidney transplantation].

M Mydlík, K Derzsiová, V Pribylincová, J Reznícek

Vnitr Lek 1996, 42(12):813-817

Urinary oxalic acid excretion was examined in 61 patients with chronic nephropathies and in 21 patients after renal transplantation with a varying mean glomerular filtration. In both groups of patients a correlation was found between the plasma oxalic acid and serum creatinine and by a hyperbolic correlation between plasma oxalic acid and creatinine clearance. Moreover the authors found a direct correlation between oxalic acid and FEoxalic acid and FE(Na)+, FEH20 and FE1-ascorbic acid in both patient groups. Various chronic nephropathies and treatment in both groups did not affect the revealed correlations. In 13 healthy subjects during the period...

[Methods of continuous extracorporeal replacement of renal function].

K Opatrný

Vnitr Lek 1996, 42(12):818-824

Methods of continuous renal replacement therapy are used to an increasing extent also in this country. The oldest one, continuous arteriovenous haemofiltration has been supplemented by continuous haemodialysis, hemodiafiltration and high-flux dialysis. An alternative of the arteriovenous vascular access is the veno-venous one. Indication for continuous renal replacement therapy are patients with acute renal failure in a critical condition, i.e. in particular patients with acute renal failure as part of multiorgan failure and patients with an unstable circulation. In this indication methods of continuous renal replacement therapy were accepted due to...

[Kidney transplantation at the Brno Transplantation Center].

D Sobotová, J Cerný, J Bucek, P Studeník, P Nĕmec, J Hökl, A Zharfbin, M Karpfel

Vnitr Lek 1996, 42(12):825-830

The transplantation activity in the Brno TC has increased significantly since 1994 and there are now 30 transplantations per 1 million population of the catchment area per year. It is, however, necessary to get more organ donors to attain the national average of 40 renal transplantations per 1 million inhabitants per year, which is also the average value in advanced European countries. With the use of immunosuppression with cyclosporin A the one, five and ten-year survival of grafts increased by 20, 35 and 15% resp., as compared with the period of conventional immunosuppression. The greatest losses of grafts were recorded in the Brno TC during the...

[Relation between creatinine clearance and glomerular filtration in long-term monitoring of individuals with kidney transplants].

O Schück, V Teplan, S Vítko, J Matl, J Skibová, M Stollová

Vnitr Lek 1996, 42(12):831-836

The authors examined in 22 subjects with a transplanted kidney after 2- to 3-month intervals for a period of 8-22 months the renal creatinine clearance (Ccr) and glomerular filtration rate (GFR) based on polyfructosan clearance (CPF). The mean value of the Ccr was 72.9 (+/- 23.3) ml/min/1.73 m/ and CPF 52.0 (+/- 19.5) ml/min/1.73 m2. The mean value of the Ccr/CPF ratio was 1.45 (+/- 0.33) and the tubular creatinine secretion (Tcr) 4.8 (+/- 5.5) mumol/min/100 ml CPF. Between values of Ccr and CPF a significant correlation was found (r = 0.752, p < 0.001). The value of the Ccr/CPF ratio in the same individual varied markedly in the course of the follow...

[Pharmacotherapy of silent myocardial ischemia in patients on hemodialysis].

J Gonsorcík, M Szakács, S Palko, M Mydlík

Vnitr Lek 1996, 42(12):837-841

Cardiovascular complications are the main causes of morbidity and mortality of patients on regular dialysis treatment. Myocardial ischaemia in those patients may be promoted apart from accelerated atherosclerosis also by many extracoronary and extracardial factors. In a group of 60 haemodialyzed patients followed up on a long-term basis silent myocardial ischaemia is encountered during 24-hour Holter monitoring in 30-40% of the examined patients. Its occurrence at the end of haemodialysis and during the early posthemodialytic period and its long persistence are typical. The authors examined 20 regularly dialyzed patients with transient depressions...

[The role of platelet-derived growth factor in progression of nephropathy].

V Spustová, A Oksa, R Dzúrik

Vnitr Lek 1996, 42(12):842-848

The platelet growth factor (PDGF) is a potent proliferative factor which stimulates the proliferation of the kidneys in particular of mesangial cells and moreover by stimulating the production of the transforming growth factor beta (TGF-beta) it stimulates also proliferation of the mesangium, glomerulosclerosis and obviously also interstitial fibrosis. By these mechanisms it participates in the progression of experimental and human nephropathies. Production of PDGF can be suppressed by a low protein diet, heparin, acetylsalicylic acid, dipyridamol, and some new antagonists are being developed. These findings were assembled in experimental investigations...

[Iron supplementation during erythropoietin therapy in patients on hemodialysis].

F Svára, S Sulková, J Kvasnićka, V Polakovic

Vnitr Lek 1996, 42(12):849-852

The development of secondary anaemia is a constant associated phenomenon of chronic renal failure. During its treatment by recombinant human erythropoietin (rHuEPO) erythropoiesis is accelerated and this increases demands on the supply of dietary erythropoietic precursors (Fe, pyridoxine, folic acid, vitamin B12). In particular as regards iron, frequently the dietary amount is not sufficient and supplementation is necessary. The objective of the present work is to compare oral and intravenous iron supplementation in the treatment of secondary anaemia by rHuEPO in patients with chronic renal failure treated by haemodialysis. A group of haemodialyzed...


Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.